【Product name】:Biosafety (prescription drug)

【Common name】:Amlodipine Benazepril Tablets (I)

【Specification】:12.5mg (including benazepril hydrochloride 10mg, amlodipine 2.5mg)

【Indications】:For the treatment of hypertension, but not newly treated hypertension. This product is suitable for patients whose blood pressure cannot be satisfactorily controlled by taking amlodipine or benazepril alone; or alternative therapy for taking amlodipine tablets and benazepril tablets at the same time.

【Product name】:Kosu (prescription drug)

【Common name】:Irbesartan Capsules

【Specification】:75mg

【Indications】:Hypertension, type 2 diabetic nephropathy with hypertension.

【Product name】:Ribenib (prescription drug)

【Common name】:Ticagrelor Tablets

【Specification】:90mg

【Indications】:Ticagrelor in combination with aspirin, in patients with acute coronary syndrome (ACS) or in patients with a history of myocardial infarction with at least one risk factor for atherothrombotic events (see PEGASUS study in clinical trials), reduces the Incidence of cardiovascular death, myocardial infarction, and stroke.

【Product name】:Ripley

【Common name】:Rivaroxaban Tablets

【Specification】:10mg

【Indications】:1. For adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE). 2. For the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults; for the reduction of DVT and/or PE in patients whose risk of recurrence of DVT and/or PE persists after completing at least 6 months of initial therapy risk of recurrence. (For patients with hemodynamically unstable PE, see [Precautions]) 3. For patients with one or more risk factors (eg: congestive heart failure, hypertension, age ≥ 75 years, diabetes, stroke, or transient cerebral history of ischemic attack) in adults with nonvalvular atrial fibrillation to reduce the risk of stroke and systemic embolism. There are limited data on the relative effectiveness of rivaroxaban compared with warfarin in reducing the risk of stroke and systemic embolism in well-controlled settings with warfarin therapy.